Reporting from the ESMO Congress 2021, Cristina Saura describes the outstanding results from the DESTINY-Breast03 study and the promising results from the TULIP trial. She explains the practice changing results in both response and PFS with trastuzumab deruxtecan, and elaborates on emerging opportunities for pre-treated patients with trastuzumab duocarmazine.
Abstracts:
LBA1 - Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized, Phase 3 Study DESTINY-Breast03 - Dr Javier Cortés, ES
LBA15 - Primary outcomes of the multi-center multinational randomized phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice combination chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer - Dr Cristina Saura Manich, ES
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
Produced by the European Society for Medical Oncology
[ Ссылка ]
